Loading stock data…
$34.44-0.35 (-1.02%)
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
LB Pharmaceuticals Inc in the Healthcare sector is trading at $34.44 with a market capitalization of $1.2B. Wall Street consensus targets $58.00 (11 analysts), implying a +68.4% move over the next 12 months. The stock is currently 31% below its 52-week high of $50.16, remaining 9.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$53.91M↓ | -$22.10M↓ | -$13.87M↓ | -$5.25M↓ | -$4.86M |
| Net Income | -$51.60M↓ | -$19.05M↓ | -$11.47M↓ | -$3.56M↑ | -$4.87M |
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in...